Casdin Capital appeared to be the VC, which was created in 2011. The leading representative office of defined VC is situated in the New York. The company was established in North America in United States.
The fund is constantly included in 2-6 investment rounds annually. This Casdin Capital works on 13 percentage points more the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 12 percentage points less often commits exit comparing to other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top amount of exits for fund were in 2018. The typical startup value when the investment from Casdin Capital is more than 1 billion dollars.
The usual cause for the fund is to invest in rounds with 7-8 partakers. Despite the Casdin Capital, startups are often financed by The Column Group, ARCH Venture Partners, Topspin Partners. The meaningful sponsors for the fund in investment in the same round are Foresite Capital, Redmile Group, Wellington Management. In the next rounds fund is usually obtained by Redmile Group, Perceptive Advisors, GV.
We also calculated 2 valuable employees in our database.
The fund has no exact preference in some founders of portfolio startups. When startup sums 1 of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Foundation Medicine, Flatiron Health, 23andMe. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Idrx | $120M | 07 Aug 2024 | - | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Thyme Care | $60M | 21 Aug 2023 | Nashville, Tennessee, United States | ||
Octave Bioscience | $32M | 26 Jul 2023 | California, United States | ||
Orbital Therapeutics | $270M | 26 Apr 2023 | - | ||
Function Oncology | $28M | 12 Apr 2023 | San Diego, California, United States | ||
iVexSol | $23M | 26 Jan 2023 | New York, New York, United States | ||
Nest Genomics (YC W22) | $8M | 10 Jan 2023 | New York, New York, United States | ||
Asimov | $175M | 05 Jan 2023 | Boston, Massachusetts, United States |
– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.
– Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.
– Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.
– Hexagon’s interdisciplinary platform combines technological advances and proprietary insights across machine learning, genomics, synthetic biology and automation to systematically discover new chemical compounds linked to known protein targets.
– Hexagon has built a database of microbial genomes that is more than twice the size of all public databases and is adding thousands of additional genomes per month.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Idrx | $120M | 07 Aug 2024 | - | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Thyme Care | $60M | 21 Aug 2023 | Nashville, Tennessee, United States | ||
Octave Bioscience | $32M | 26 Jul 2023 | California, United States | ||
Orbital Therapeutics | $270M | 26 Apr 2023 | - | ||
Function Oncology | $28M | 12 Apr 2023 | San Diego, California, United States | ||
iVexSol | $23M | 26 Jan 2023 | New York, New York, United States | ||
Nest Genomics (YC W22) | $8M | 10 Jan 2023 | New York, New York, United States | ||
Asimov | $175M | 05 Jan 2023 | Boston, Massachusetts, United States |
